Market Overview

UPDATE: Wedbush Raises PT to $5 on Xoma on Gevokizumab Initial Efficacy

Related XOMA
12 Biggest Mid-Day Losers For Monday
Mid-Day Market Update: C R Bard Surges On Acquisition News; XOMA Shares Plunge

Wedbush reiterated its Outperform rating on Xoma (NASDAQ: XOMA) and raised its price target from $4 to $5.

Wedbush commented, "Xoma announced that Gevokizumab demonstrated initial clinical efficacy as a treatment candidate for severe inflammatory acne. Interim results from 92 of 125 enrolled patients to date showed that the higher of two doses (0.2 and 0.6 mg/kg) of Gevokizumab demonstrated a consistent mean reduction from an average baseline of 31 inflammatory lesions to 19 through Day 84 with statistically significant reduction on Day 42 (p=0.077 based on 80% power to achieve p<0.10)."

Xoma closed at $2.77 on Friday.

Latest Ratings for XOMA

Mar 2017WedbushReiteratesNeutral
Nov 2016WedbushDowngradesOutperformNeutral
Jul 2015JefferiesDowngradesBuyHold

View More Analyst Ratings for XOMA
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (XOMA)

View Comments and Join the Discussion!